139 related articles for article (PubMed ID: 11587278)
1. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer.
Cole SR; Young GP
Med J Aust; 2001 Aug; 175(4):195-8. PubMed ID: 11587278
[TBL] [Abstract][Full Text] [Related]
2. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer.
Cole SR; Young GP; Esterman A; Cadd B; Morcom J
J Med Screen; 2003; 10(3):117-22. PubMed ID: 14561262
[TBL] [Abstract][Full Text] [Related]
3. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community.
Hughes K; Leggett B; Del Mar C; Croese J; Fairley S; Masson J; Aitken J; Clavarino A; Janda M; Stanton WR; Tong S; Newman B
Aust N Z J Public Health; 2005 Aug; 29(4):358-64. PubMed ID: 16222934
[TBL] [Abstract][Full Text] [Related]
4. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of personalised decision support delivered via the internet for bowel cancer screening with a faecal occult blood test: the effects of tailoring of messages according to social cognitive variables on participation.
Wilson CJ; Flight IH; Turnbull D; Gregory T; Cole SR; Young GP; Zajac IT
BMC Med Inform Decis Mak; 2015 Apr; 15():25. PubMed ID: 25886492
[TBL] [Abstract][Full Text] [Related]
6. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner.
Cole SR; Young GP; Byrne D; Guy JR; Morcom J
J Med Screen; 2002; 9(4):147-52. PubMed ID: 12518003
[TBL] [Abstract][Full Text] [Related]
7. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.
Church TR; Yeazel MW; Jones RM; Kochevar LK; Watt GD; Mongin SJ; Cordes JE; Engelhard D
J Natl Cancer Inst; 2004 May; 96(10):770-80. PubMed ID: 15150305
[TBL] [Abstract][Full Text] [Related]
9. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice.
Multicentre Australian Colorectal-neoplasia Screening (MACS) Group
Med J Aust; 2006 Jun; 184(11):546-50. PubMed ID: 16768659
[TBL] [Abstract][Full Text] [Related]
10. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
11. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis.
Vart G; Banzi R; Minozzi S
Prev Med; 2012 Aug; 55(2):87-92. PubMed ID: 22634386
[TBL] [Abstract][Full Text] [Related]
12. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
[TBL] [Abstract][Full Text] [Related]
13. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
16. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
17. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
18. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
19. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
Todorov K; Wilson C; Sharplin G; Corsini N
Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
